middle.news
Radiopharm Theranostics Advances Brain Cancer Imaging with 92% MRI Concordance
9:28am on Wednesday 28th of January, 2026 AEDT
•
Healthcare
Read Story
Radiopharm Theranostics Advances Brain Cancer Imaging with 92% MRI Concordance
9:28am on Wednesday 28th of January, 2026 AEDT
Key Points
92% MRI concordance in Phase 2b RAD 101 brain metastases imaging trial
Dose escalation approved for RAD 202 and RAD 204 Phase 1 trials
New Phase 1 trials initiated for RV-01 and RAD 402
Cash reserves of $34.52 million provide runway into 2027
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
RADIOPHARM THERANOSTICS (ASX:RAD)
OPEN ARTICLE